In an amazing story out of the London Times, medical researchers report that a stem cell therapy offering “natural” breast enlargement is to be made available to British women for the first time.

The story confirms that an “increase of one cup size is likely”, with the potential for even greater larger cup sizes, as the technique improves.

Professor Kefah Mokbel, a consultant breast surgeon at the London Breast Institute at the Princess Grace hospital, who is in charge of the project, will treat 10 patients from May. He predicts private patients will be able to pay for the procedure within six months at a cost of about £6,500.

On the one hand, researchers insist that the focus of the breast enhancement technique is focused on cancer victims. Yet, everyone seems to understand the short-term potential for use of the breast enlargement procedure in the larger population.

The same technique has been used in Japan for six years, initially for cancer victims, but more recently as cosmetic breast augmentation for healthy women.

I will followup this story, re any US connections, but reading the facts from the London Times, this new reality seems to have major ‘legs’ and will take on a momentum of its own for women who can afford the treatments.

Americans are leaving the US in larger-than-ever numbers, seeking medical treatment offshore, for primarily financial savings. I see this procedure being a new ‘product’ on the medical menu, even if it is banned in the US.

Stem-cell breast augmentation may emerge as a new option for women who won’t get implants, for fear of losing sensation, or having ‘large’ but not natural-feeling breasts. Also, implants have a spotty record with internal leaking and other health-related issues.

We must remember, that in the case of this new breast-enhancement technique, scientists are recommending long-term studies be done, before it’s considered safe for the general population.

It seems, though, that the science will be compelling and doctors will respond to “need” for the procedure.

This is a major news story, and the timeline to market, appears to be a short one. Anne